Loading…
ASA is a brand name for Aspirin (also known as Acetylsalicylic Acid), supplied as a tablet (delayed-release). The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS…
Verbatim from this product's HC label. Tap a section to expand.
Patients who are hypersensitive to ASA, salicylates, non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, antipyretics or other ingredients in the product or component of the container. For a complete listing, see DOSAGE FORMS, COMPOSITION AND PACKAGING section of the product monograph.
Acute gastrointestinal ulcer History of gastrointestinal ulcers Hemorrhagic diathesis Active or Severe hepatic failure, renal failure, or congestive heart failure Patients with a history of asthma induced by the administration of salicylates or substances with a similar action, notably non-steroidal anti-inflammatory drugs Combination with methotrexate at doses of 15mg/week or more (see DRUG INTERACTIONS); Last trimester of pregnancy (see “Special Populations”) WARNINGS AND PRECAUTIONS General ASA is one of the most frequent causes of accidental poisonings in toddlers and infants.
Tablets or caplets should be kept well out of the reach of children. g. renal vascular disease, congestive heart failure, volume depletion, major surgery, sepsis or major haemorrhagic events) a history of bleeding tendencies, significant anemia and/or hypothrombinemia concomitant treatment with anticoagulants (see DRUG INTERACTIONS) concomitant treatment with NSAIDs, such as ibuprofen and naproxen in patients taking ASA regimen (see DRUG INTERACTIONS) Hypersensitivity ASA may precipitate bronchospasm and induce asthma attacks or other hypersensitivity reactions.
Risk factors are present bronchial asthma, hay fever, nasal polyps, or chronic respiratory disease. g. cutaneous reactions, itching, urticaria) to other substances. Product Monograph - ASA Page 5 of 39 Hematologic Due to effect on platelet aggregation, ASA may be associated with an increased risk of bleeding.
Caution is necessary when salicylates and anticoagulants are prescribed concurrently, as salicylates can depress the concentration of prothrombin in the plasma. g. dental extractions).
Special Populations Women attempting to conceive:
During the first and second trimester of pregnancy, acetylsalicylic acid containing drugs should not be given unless clearly necessary. If acetylsalicylic acid containing drugs are used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and duration of treatment as short as possible.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Aspirin in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Based on the limited published data available, the studies in humans showed no consistent effect of acetylsalicylic acid on impairment of fertility and there is no conclusive evidence from animal studies.
Pregnant Women:
Acetylsalicylic acid inhibits prostaglandin synthesis. Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal development. Data from epidemiological studies raise concern about an increased risk of miscarriage and of malformations after the use of a prostaglandin synthesis inhibitor in early pregnancy.
The risk is believed to increase with dose and duration of therapy. Available data do not support any association between intake of acetylsalicylic acid and an increased risk for miscarriage. For acetylsalicylic acid the available epidemiological data regarding malformation are not consistent, but an increased risk of gastroschisis could not be excluded.
A prospective study with exposure in early pregnancy (1st-4th month) of about 14,800 mother-child pairs has not yielded any association with an elevated rate of malformations. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the foetus to: cardiopulmonary toxicity (with premature closure of the ductus ateriosus and pulmonary hypertension); renal dysfunction, which may progress to renal failure with oligo-hydroamniosis; Use of any prostaglandin synthesis inhibitors at the end of pregnancy may expose the mother and the child to: Product Monograph - ASA Page 6 of 39 possible prolongation of bleeding time, an anti-aggregating effect which may occur even after very low doses; inhibition of uterine contractions resulting in delayed or prolonged labour.
Consequently, acetylsalicylic acid is contraindicated in the third trimester of pregnancy.
Nursing Women:
ASA and its metabolites pass into breast milk in small quantities. Since no adverse effects on the infant have been observed after occasional use, interruption of breast-feeding is usually unnecessary. However, on regular use or on intake of high doses, breast feeding should be discontinued early.
Pediatrics:
A possible association between Reye's syndrome and the use of salicylates has been suggested but not established. Reye's syndrome has also occurred in many patients not exposed to salicylates. ASA should not be used in children and teenagers for viral infections with or without fever without consulting a physician.
In certain viral illnesses, especially influenza A, influenza B and varicella, there is a risk of Reye’s syndrome, a very rare but possibly life- threatening illness requiring immediate medical action. The risk may be increased when ASA is given concomitantly; however, no causal relationship has been proven.
Should persistent vomiting occur with such diseases; this may be a sign of Reye’s syndrome.
Low Uric Acid Excretion:
At low doses, ASA reduces excretion of uric acid. This can trigger gout in patients who already tend to have low uric acid excretion.
Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency:
In patient suffering from glucose-6-phosphate dehydrogenase (G6PD) […]